Neurobiology of Depression and Antidepressant Mechanisms

Major depressive disorder arises from complex interactions among genetic, environmental and neurobiological factors. At the cellular level, alterations in monoaminergic signalling, neurotrophic support and synaptic connectivity converge to yield the core features of depression, including persistent low mood, cognitive impairment and anhedonia. Dysregulation of the hypothalamic–pituitary–adrenal axis and heightened neuroinflammatory responses further compromise neuronal integrity, particularly within prefrontal cortex and hippocampal circuits. Traditional antidepressants, such as selective serotonin reuptake inhibitors, act over weeks by gradually restoring neurotransmitter balance and promoting neuroplastic changes via factors like brain-derived neurotrophic factor. In contrast, rapid-acting agents—including NMDA receptor antagonists and GABAergic modulators—trigger local protein synthesis through pathways such as mTORC1, leading to swift restoration of synaptic function. Advances in understanding network-level biomarkers, from aberrant oscillatory activity to altered functional connectivity, are opening avenues for personalised interventions and novel pharmacotherapies that target specific molecular and circuit mechanisms.

Research from Nature Portfolio

Chronic administration of a widely used serotonin reuptake inhibitor has been shown to reinstigate synaptic protein expression via activation of the mTOR signalling cascade in a region-dependent manner. In models of prolonged stress, treatment reversed reductions in synapsin I and PSD-95 within hippocampus and amygdala but not in frontal cortex, highlighting the importance of local protein synthesis in mediating antidepressant efficacy and circuit restoration.

Neurobiology of Depression and Antidepressant Mechanisms publication trend

The graph below shows the total number of articles in neurobiology of depression and antidepressant mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

mTOR signalling: A kinase-driven pathway that regulates synaptic protein synthesis and neuronal growth in response to extracellular cues.

Synaptic plasticity: The capacity of synapses to strengthen or weaken over time, underpinning learning, memory and mood regulation.

NMDA receptor antagonists: Compounds that block N-methyl-D-aspartate receptors, promoting rapid antidepressant effects via downstream activation of protein-synthesis pathways.

Gamma oscillations: High-frequency brain rhythms (30–100 Hz) measurable by EEG, linked to cognitive processing and emerging as biomarkers in depression.

Neuroinflammation: Activation of glial cells and release of pro-inflammatory mediators that can disrupt neuronal function and contribute to depressive pathology.

Hypothalamic–pituitary–adrenal (HPA) axis: The stress-response system whose dysregulation leads to sustained cortisol release and impaired neuroplasticity.

References

1. Molecular signatures of premature aging in Major Depression and Substance Use Disorders. Scientific Data (2024).
2. Gamma oscillations as a biomarker for major depression: an emerging topic. Translational Psychiatry (2018).
3. Fluoxetine regulates mTOR signalling in a region-dependent manner in depression-like mice. Scientific Reports (2015).
4. Hippocampal CA1 βCaMKII mediates neuroinflammatory responses via COX-2/PGE2 signaling pathways in depression. Journal of Neuroinflammation (2018).
5. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology (2020).
6. A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice. eNeuro (2017).